CL2004000496A1 - Composicion farmaceutica liquida de administracion oral que comprende agua, acido metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico, y un agente de suspension, con un ph entre 4,5 y 5,5; metodo de preparacion; uso para tratar un trastorno dependiente - Google Patents

Composicion farmaceutica liquida de administracion oral que comprende agua, acido metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico, y un agente de suspension, con un ph entre 4,5 y 5,5; metodo de preparacion; uso para tratar un trastorno dependiente

Info

Publication number
CL2004000496A1
CL2004000496A1 CL200400496A CL2004000496A CL2004000496A1 CL 2004000496 A1 CL2004000496 A1 CL 2004000496A1 CL 200400496 A CL200400496 A CL 200400496A CL 2004000496 A CL2004000496 A CL 2004000496A CL 2004000496 A1 CL2004000496 A1 CL 2004000496A1
Authority
CL
Chile
Prior art keywords
fluoroanilino
phenylacetic
chlorine
oral administration
treat
Prior art date
Application number
CL200400496A
Other languages
English (en)
Inventor
Patrick Khaled Maha Y Forenzo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2004000496(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2004000496A1 publication Critical patent/CL2004000496A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PROPORCIONAN COMPOSICIONES QUE COMPRENDEN SUSPENSIONES ACUOSAS DE ACIDO 5-METIL-2-(22--CLORO-62--FLUOROANILINO)FENILACETICO ADECUADAS PARA ADMINISTRACION ORAL. TAMBIEN SE PROPORCIONAN METODOS PARA HACER DICHAS COMPOSICIONES Y METODOS PARA SU ESTABILIZACION.
CL200400496A 2003-03-12 2004-03-11 Composicion farmaceutica liquida de administracion oral que comprende agua, acido metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico, y un agente de suspension, con un ph entre 4,5 y 5,5; metodo de preparacion; uso para tratar un trastorno dependiente CL2004000496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45414503P 2003-03-12 2003-03-12

Publications (1)

Publication Number Publication Date
CL2004000496A1 true CL2004000496A1 (es) 2005-01-14

Family

ID=32990870

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400496A CL2004000496A1 (es) 2003-03-12 2004-03-11 Composicion farmaceutica liquida de administracion oral que comprende agua, acido metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico, y un agente de suspension, con un ph entre 4,5 y 5,5; metodo de preparacion; uso para tratar un trastorno dependiente

Country Status (30)

Country Link
US (2) US20060094787A1 (es)
EP (1) EP1603550B1 (es)
JP (1) JP4580921B2 (es)
KR (1) KR20050109077A (es)
CN (1) CN100345536C (es)
AR (1) AR043536A1 (es)
AT (1) ATE418332T1 (es)
AU (1) AU2004218921B2 (es)
BR (1) BRPI0408270A (es)
CA (1) CA2518393A1 (es)
CL (1) CL2004000496A1 (es)
DE (1) DE602004018622D1 (es)
EC (1) ECSP055998A (es)
ES (1) ES2318277T3 (es)
HK (1) HK1086492A1 (es)
HR (1) HRP20050787A2 (es)
IL (1) IL170518A (es)
IS (1) IS2658B (es)
MA (1) MA27670A1 (es)
MX (1) MXPA05009686A (es)
MY (1) MY139455A (es)
NO (1) NO20054662L (es)
NZ (1) NZ542218A (es)
PE (1) PE20041063A1 (es)
PT (1) PT1603550E (es)
RU (1) RU2363462C2 (es)
TN (1) TNSN05222A1 (es)
TW (1) TWI327913B (es)
WO (1) WO2004080451A1 (es)
ZA (1) ZA200506750B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1673079A1 (en) * 2003-10-08 2006-06-28 Novartis AG Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
KR100900915B1 (ko) * 2007-05-07 2009-06-05 이연제약주식회사 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
CN101854913A (zh) * 2007-11-12 2010-10-06 诺瓦提斯公司 含有缬沙坦的液体组合物
EP2926810A1 (en) * 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical formulations of loxoprofen
CN109906079B (zh) * 2016-06-16 2022-09-30 库蒂斯制药公司 用于质子泵抑制剂混悬剂的组合物和方法
US20190282500A1 (en) * 2016-09-09 2019-09-19 Cutispharma, Inc. Suspensions and diluents for metronidazole and baclofen
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. METHODS OF TREATING GLIOBLASTOMA
WO2019067991A1 (en) * 2017-09-29 2019-04-04 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND USES THEREOF
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5840768A (en) * 1997-06-04 1998-11-24 Fmc Corporation MCC: alginate pharmaceutical suspensions
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
MXPA04006608A (es) * 2002-01-07 2004-10-04 Pharmacia Corp Tratamiento de dolor, inflamacion y trastornos relacionados con inflamacion con una combinacion de inhibidor selectivo de ciclooxigenasa-2 y aspirina.
CA2480832A1 (en) * 2002-04-05 2003-10-23 Nitromed, Inc. Nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
MXPA05009686A (es) 2005-10-20
TW200505429A (en) 2005-02-16
RU2363462C2 (ru) 2009-08-10
ES2318277T3 (es) 2009-05-01
TNSN05222A1 (en) 2007-06-11
WO2004080451A1 (en) 2004-09-23
EP1603550B1 (en) 2008-12-24
IS8049A (is) 2005-09-28
NO20054662D0 (no) 2005-10-11
US20060094787A1 (en) 2006-05-04
JP2006519811A (ja) 2006-08-31
TWI327913B (en) 2010-08-01
NO20054662L (no) 2005-12-05
IL170518A (en) 2010-11-30
KR20050109077A (ko) 2005-11-17
HRP20050787A2 (en) 2006-12-31
IS2658B (is) 2010-08-15
CA2518393A1 (en) 2004-09-23
ECSP055998A (es) 2006-01-27
CN1756541A (zh) 2006-04-05
HK1086492A1 (en) 2006-09-22
CN100345536C (zh) 2007-10-31
DE602004018622D1 (de) 2009-02-05
AU2004218921A1 (en) 2004-09-23
ZA200506750B (en) 2007-02-28
MA27670A1 (fr) 2005-12-01
ATE418332T1 (de) 2009-01-15
JP4580921B2 (ja) 2010-11-17
PT1603550E (pt) 2009-03-20
AR043536A1 (es) 2005-08-03
BRPI0408270A (pt) 2006-03-07
US20090048344A1 (en) 2009-02-19
EP1603550A1 (en) 2005-12-14
NZ542218A (en) 2009-01-31
RU2005131310A (ru) 2006-05-10
PE20041063A1 (es) 2005-03-07
MY139455A (en) 2009-10-30
AU2004218921B2 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
ECSP044974A (es) Formulación de suspensión oral estabilizada
ATE429210T1 (de) Orale flüssige zusammensetzungen
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
DK1311256T3 (da) Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
BR9916076A (pt) Composição adequada para aplicação tópica, uso de uma composição tópica métodos para melhorar o distúrbio do estìmulo sexual feminino, e para intensificar o estìmulo sexual feminino, e a resposta sexual feminina, artigo de manufatura
TW200505478A (en) Immunoglobulin formulation and method of preparation thereof
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
CL2004000496A1 (es) Composicion farmaceutica liquida de administracion oral que comprende agua, acido metil-2-(2'-cloro-6'-fluoroanilino) fenilacetico, y un agente de suspension, con un ph entre 4,5 y 5,5; metodo de preparacion; uso para tratar un trastorno dependiente
AR052855A1 (es) Composiciones para el cuidado bucal que contienen un extrato de eucalyptus
BR0115354A (pt) Composições de suspensão de lìquidos estáveis, método de preparo e uso das mesmas
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
SE0302546D0 (sv) New compounds
EE200200252A (et) Antikehade kasutamine vaktsiinidena, antikehi sisaldavad farmatseutilised kompositsioonid, meetod antikehapreparaadi valmistamiseks ja meetod farmatseutilise kompositsiooni valmistamiseks
MA27850A1 (fr) Preparations pharmaceutiques contenant de l'amoxicilline et du clavulanate
DE60217903D1 (de) Flüssige pharmazeutische zusammensetzungen auf wasserbasis in suspensionsform zur oralen verabreichung von ibuprofen
ITTO20010028A0 (it) Metodo per aumentare l'attivita' antitumorale di una sostanza contenente amigdalina, composizione contenente una sostanza con contenuto aume
PT1283042E (pt) Preparação líquida aquosa de pranoprofeno
SE9902742D0 (sv) New pharmaceutical formultion
TW200509990A (en) Pharmaceutical formulations
ITMI942094A0 (it) Procedimento microbiologico per la preparazione di 3-oxo-4-azasteroidi-17beta-carbossi sostituiti e uso dei prodotti come inibitori dell'enzima 5alfa-riduttasi
TH77904A (th) สารผสมทางเภสัชกรรม
ITMI20030064A1 (it) Uso dei derivati dell'acido idrossamico per la preparazione
ITMI20011634A1 (it) Uso dei derivati dell'acido idrossamico per la preparazione di medicamenti anti-tumorali